Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Sep 2018 Status changed from active, no longer recruiting to discontinued.
17 Sep 2018 According to a Realm Therapeutics media release, the overall results of this trial did not meet the threshold for continued investment and the company decided to discontinue all of the drug development programs, which are based on the Company's proprietary technology.
14 Aug 2018 According to Realm Therapeutics media release, company announced preliminary top-line data from this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com